Modulating the expression or activity of MPO, NE, or PR3 through genetic manipulation or pharmacological approaches presents a promising therapeutic strategy for ameliorating pathological changes in MASH (64, 96). Here, PRTN3 is linked to metabolic dysfunction-associated steatohepatitis.